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Case
Report

Thoratec HeartMate II® Left Ventricular Assist
Device Implantation in Patient with Patent
Ventriculoperitoneal Shunt
Kentaro Yamane, MD, PhD, Linda J. Bogar, MD, Shigeki Tabata, MD, PhD, and
Hitoshi Hirose, MD, PhD.

We report a case of HeartMate II® left ventricular assist device (LVAD) implantation as a
destination therapy in a patient with a patent ventriculoperitoneal (VP) shunt after being suffered from subarachnoid hemorrhage. Because the patient’s VP shunt was running through
her right anterior chest and abdominal wall, a driveline exit site was selected in her left upper
quadrant to avoid unnecessary perioperative complication in relation to the patent VP shunt
tube. Tailored driveline placement was a key element of this LVAD implantation in this
already sick patient with multiple comorbidities.
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Introduction
With the continued shortage of available donor hearts
and constantly increasing population of heart failure patients, an application of left ventricular assist device
(LVAD) as a destination therapy became an important
option for heart failure patients.1) With a miniatualization
and an improving profile of the implantable LVADs, even
patients with multiple comorbidities or social issues may
become candidates to have these devices as a destination
therapy. Once a destination therapy is selected to such patients, judicious strategy for device implantation should
be made for individual patient’s basis, since these patients
are quite decompensated and carry high risk of postoperative complication. We report a case of LVAD implantation in a patient with a significant past medical history of
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intracranial bleeding and a patent ventriculoperitoneal
(VP) shunt.

Case Presentation
A 62-year-old female with a past medical history of type
2 diabetes mellitus, hypertension, who previously had undergone aortic valve replacement and mitral valve repair,
developed non-ischemic cardiomyopathy, which was not
amenable to outpatient management. The patient had multiple hospital admissions due to heart failure and treated
with an inotrope support. Preoperative characteristics of
the patient on home infusion therapy of 5 mcg/kg/min of
dobutamine are shown in Table 1. She also has a significant history of a subarachnoid hemorrhage treated with
coiling of an aneurysm in the brain and VP shunt placement. Of note, her VP shunt tube had malfunctioned once
and caused her a temporary neurological issue and required revision in the past. However, the patient did not
have any gross neurological deficit and lived independently at this point. Her social support was evaluated and
thought to be inadequate for heart transplantation. Thus,
LVAD implantation was offered as a destination therapy.
The HeartMate II® LVAD (Thoratec Corporation, Pleasanton, CA, Fig. 1) is a continuous flow ventricular assist
device approved for destination therapy by the federal
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Table 1 Preoperative characteristics of the patient
Variable
Height
Weight
Body surface area
Heart rate
Blood pressure
Right heart catheterization
Right atrium
Pulmonary artery
Pulmonary capillary wedge pressure
Fick cardiac index
Fick cardiac index (Before dobutamine infusion)
Pulmonary vascular resistance index
Right ventricular stroke work index
Transthoracic echocardiogram
Ejection fraction
Fractional shortening
Left ventricular internal diastolic diameter
Left ventricular internal systolic diameter

Food and Drug Administration in 2010. Considering the
patient’s body size and recently proven advantages of
continuous flow LVAD over pulsatile flow LVADs, regarding the reliability of the device, improved survival
and quality of life of the patients,2) we selected the HeartMate II LVAD for this patient.
Preoperative computed tomography scan of her chest
and abdomen showed the VP shunt tube running in the
subcutaneous tissue of the right anterior chest and abdomen. The tube runs about 3 cm lateral to the midline, and
then it enters into the peritoneal cavity at the right upper
quadrant. A redo sternotomy was performed after the exposure of the right femoral artery. Adhesions were taken
down and a pocket for the HeartMate II LVAD was created in the standard manner. Then the driveline was tunneled to make a gentle curve and to exit to the left upper
quadrant. An extreme care was taken not to get too close
to the VP shunt tube, while the length of the subcutaneous tunnel to be as long as possible to cover the velour
part of the driveline (Figs. 2 and 3). The outflow graft
was sewn on the ascending aorta under a partial clamping. The right femoral artery was cannulated and the patient was placed on the cardiopulmonary bypass (CPB).
The inflow of the LVAD was placed into the apical sawing cuff, and after deairing, the LVAD was started and
then the patient was weaned off from CPB. Postoperatively, the patient became oliguric and required a 6-day
course of a continuous venovenous hemodialysis. Because
of significant coagulopathy, her chest was closed on the
postoperative day 4. Due to her inability to be weaned
2

165 cm
64.9 kg
1.71 m2
75 /min
100/57 mmHg
a 12 / v 12 / mean 10 mmHg
75/30 mmHg, mean 50 mmHg
a 27 / v 37 / mean 30 mmHg
3.0 L/min/m2
2.0 L/min/m2
6.7 Wood units
467 mmHg·mL/m2
15 %
6%
78 mm
73 mm

Fig. 1 HeartMate II® continuous flow left ventricular assist
device (Figure courtesy of Thoratec Corp).
*This figure is reprinted from the HeartMate II operating
manual. ©Thoratec Corp.

from the ventilator, a tracheostomy and percutaneous endoscopic gastrostomy (PEG) tube were placed on the
postoperative day 12. Her tracheostomy tube and PEG
tube was decannulated successfully on the postoperative
days 48 and 55, respectively, before being discharged to
home on postoperative day 60. The patient is currently
functionally independent with her activities of daily life
and competent with all aspects of HeartMate II LVAD
operation.
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Fig. 2 Computed tomography of the abdomen showing generous
distance between the ventriculoperitoneal shunt tube
(arrowhead) and the driveline of the ventricular assist
device (arrow).

Discussion
Although the newer generation of implantable, continuous flow devices has accomplished to lower the perioperative complication rate than that of the pulsatile flow devices, major complications such as bleeding, infection,
thromboembolism, and gastrointestinal tract bleeding are
still considerable complications in the continuous flow
devices.3) Because patients undergoing destination LVAD
placement carry high likelihood of suffering from postoperative complications, diligent efforts to reduce the
postoperative complication are required to improve the
outcome.
Our patient already had a history of revision of the VP
shunt tube previously. The use of electrocautery close to a
driveline of the LVAD is strongly discouraged, because
energy force can injure the driveline and cause malfunction of the implantable LVAD. If, in the future, this patient does require revision of the VP shunt, the proximity
of the LVAD driveline to the VP shunt should be avoided
to minimize the risk of inadvertent injury of the driveline
from an electrocautery or surgical instruments. If a patient has known intra-abdominal disease such as cholecystolithiasis, and there is a possibility of future requirement of an invasive treatment, a prophylactic treatment
may be considered. Similarly, the PEG tube placement in
our patient was carefully performed not to injure the
driveline of the LVAD.
Infection rate of the driveline has been reported as
12.5%–17.3%.3,4) In our patient, infection of either the

Fig. 3 Chest X-ray showing a gentle curve of the subcutaneous driveline alignment.

driveline or the VP shut tube could affect each other, and
may lead to a devastating central nervous system infection or mediastinitis. An appropriate alignment of the
driveline will contribute to reduce the chance of driveline
and device infection or the driveline related device malfunction.5) The considerations for selecting a driveline
exit site before operative planning should include: (i) an
enough length of the subcutaneous tunnel; (ii) no kinking
or sharp bending in the entire length of the drive line; (iii)
not to compromise the patients’ clothing; and, (iv) ease of
the exit site care by patients and their caregivers. In our
patient, any inadvertent injury of the VP shunt tube could
cause neurological or other complications, so we decided
to place the driveline exit site far from the VP shunt and
in her left upper quadrant.
Although our patient recovered from multiple postoperative complications, any additional complication might
further compromise her postoperative course or might
even cause mortality. The meticulous surgical strategy of
device implantation is important for heart failure patients
who are already sick enough from preoperative comorbidities and decompensated cardiac function.
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